Xenon Pharmaceuticals Inc. (XENE) short interest & options flow
NASDAQXENE short interest surges 33% over the past week to 9.6% of float, driven by enrollment halt in psychiatric trials following safety concerns. Cost to borrow remains benign at 0.59%, but availability at 3,093% of short interest suggests ample shares available to borrow despite the buildup.
- Market cap
- $4.14B
- Next earnings
- 26 Feb 2027
Key data as of 12 Nov 2026
Latest signals on XENE
- Short Interest
XENE short interest surges 33% over the past week to 9.6% of float, driven by enrollment halt in psychiatric trials following safety concerns. Cost to borrow remains benign at 0.59%, but availability at 3,093% of short interest suggests ample shares available to borrow despite the buildup.
XENE news and analysis
RSSNo long-form analysis yet for XENE. Pulse alerts and the live data picture are available on ORTEX.
Open XENE on ORTEX →Want the live picture for XENE?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XENE — free to start on ORTEX.
Sign up for free →Open XENE on ORTEX